

ISCT 2018 – Product Theatre Presentation

Presented on Friday, May 4, 2018 at 10:15AM-10:45AM

Biolaminin™ 521 CTG – a biologically relevant culture matrix, enabling pre-clinical research protocols to be translated and used for clinical trials

Therese Kallur, PhD, Business development manager, BioLamina, Sweden

As an extension of our portfolio of hr laminin cell culture substrates, we now offer a cell therapy grade (CTG) laminin-521 matrix, Biolaminin™ 521 CTG, for use in research and manufacturing of Cell, Gene, or Tissue-Based Products. BioLaminin 521 CTG is produced according to FDA and EMEA guidelines (USP <1043>) and is aimed to be an ancillary material in the manufacturing cell products for therapeutic use. It is designed to aid users in the qualification process of raw material.

Biolaminin 521 CTG is a xeno-free and provides a defined surface for feeder-free culture of human pluripotent stem cells (ESC and iPSC), MSCs, most anchorage-dependent progenitors and differentiated cells such as RPE, hepatocytes, cardiomyocytes and neurons. The Biolaminin 521 substrate recreates a biologically relevant milieu *in vitro*, promoting high survival and robust single-cell or colony expansion of human pluripotent stem cells, and subsequent cell lineage specification. The cells grow with maintained pluripotency, genetic integrity in a homogeneous monolayer, easy to monitor and maintain. The substrate is robust, flexible and compliant with any culture medium and protocol. It allows an operator-independent culture maintenance and reliable, standardized protocols which can easily be adapted to automation platforms.

